ReRx Therapeutics

Developer of oral therapeutics intended to transfer clinical outcomes of patients with severe metabolic disorders. The company targets severe metabolic diseases like Obesity, Type 2 Diabetes Mellitus, Metabolic Syndrome, and NASH/NAFLD, enabling doctors to improve clinical outcomes for ACC inhibition.